About Alpha-mannosidase 2
Alpha-mannosidase 2 (MAN2A1) is a protein
from Homo sapiens identified by UniProt accession
Q16706, 1144 residues long.
MolForge cross-references it against 0 known binders and
245 disease associations.
Target properties
| Protein name | Alpha-mannosidase 2 |
|---|
| UniProt accession | Q16706 |
|---|
| Gene | MAN2A1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1144 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (245)
Diseases linked to this target (Open Targets).
- self reported educational attainment · score 0.41
- schizophrenia · score 0.38
- COVID-19 · score 0.37
- mathematical ability · score 0.33
- alcohol-related disorders · score 0.30
- neurodegenerative disease · score 0.30
- cognitive function measurement · score 0.28
- intelligence · score 0.28
- hypothyroidism · score 0.27
- Alzheimer disease · score 0.26
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q16706-F1 | alphafold | PREDICTED | 89.98 | — |
Amino-acid sequence (1144 residues)
MKLSRQFTVF GSAIFCVVIF SLYLMLDRGH LDYPRNPRRE GSFPQGQLSM LQEKIDHLER LLAENNEIIS NIRDSVINLS ESVEDGPKSS QSNFSQGAGS HLLPSQLSLS VDTADCLFAS QSGSHNSDVQ MLDVYSLISF DNPDGGVWKQ GFDITYESNE WDTEPLQVFV VPHSHNDPGW LKTFNDYFRD KTQYIFNNMV LKLKEDSRRK FIWSEISYLS KWWDIIDIQK KDAVKSLIEN GQLEIVTGGW VMPDEATPHY FALIDQLIEG HQWLENNIGV KPRSGWAIDP FGHSPTMAYL LNRAGLSHML IQRVHYAVKK HFALHKTLEF FWRQNWDLGS VTDILCHMMP FYSYDIPHTC GPDPKICCQF DFKRLPGGRF GCPWGVPPET IHPGNVQSRA RMLLDQYRKK SKLFRTKVLL APLGDDFRYC EYTEWDLQFK NYQQLFDYMN SQSKFKVKIQ FGTLSDFFDA LDKADETQRD KGQSMFPVLS GDFFTYADRD DHYWSGYFTS RPFYKRMDRI MESHLRAAEI LYYFALRQAH KYKINKFLSS SLYTALTEAR RNLGLFQHHD AITGTAKDWV VVDYGTRLFH SLMVLEKIIG NSAFLLILKD KLTYDSYSPD TFLEMDLKQK SQDSLPQKNI IRLSAEPRYL VVYNPLEQDR ISLVSVYVSS PTVQVFSASG KPVEVQVSAV WDTANTISET AYEISFRAHI PPLGLKVYKI LESASSNSHL ADYVLYKNKV EDSGIFTIKN MINTEEGITL ENSFVLLRFD QTGLMKQMMT KEDGKHHEVN VQFSWYGTTI KRDKSGAYLF LPDGNAKPYV YTTPPFVRVT HGRIYSEVTC FFDHVTHRVR LYHIQGIEGQ SVEVSNIVDI RKVYNREIAM KISSDIKSQN RFYTDLNGYQ IQPRMTLSKL PLQANVYPMT TMAYIQDAKH RLTLLSAQSL GVSSLNSGQI EVIMDRRLMQ DDNRGLEQGI QDNKITANLF RILLEKRSAV NTEEEKKSVS YPSLLSHITS SLMNHPVIPM ANKFSSPTLE LQGEFSPLQS SLPCDIHLVN LRTIQSKVGN GHSNEAALIL HRKGFDCRFS SKGTGLFCST TQGKILVQKL LNKFIVESLT PSSLSLMHSP PGTQNISEIN LSPMEISTFR IQLR
Explore Alpha-mannosidase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets